AUM Biosciences

NASDAQ-bound Singaporean biotech firm AUM Biosciences aims to be key player in global precision oncology space

In the interview ahead of the company’s de-SPAC, CEO also shared about the challenges and opportunities as the precision oncology space, the company's immediate plan following its listing. He also shared his views on the biotech landscape in Southeast Asia and gave several suggestions for for companies, governments, and investors for the biotech industry in…

Singapore’s AUM Biosciences plans to go public via SPAC merger

Singapore-based biotechnology company AUM Biosciences (AUM) plans to go public on Nasdaq via a special purpose acquisition company (SPAC) merger with Mountain Crest Acquisition Corp.